Journal of Multiple Sclerosis

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds* and Oman Godsy

In the dynamic realm of Multiple Sclerosis (MS) treatment, the spotlight has recently been cast on the long-term effects of Glatiramer Acetate (GA) and interferons-ß (IFNs), particularly within the confines of the UK Multiple Sclerosis Risk Sharing Scheme (RSS). This article embarks on an exhaustive exploration, offering a detailed and comprehensive perspective on the cost-effectiveness of GA for Relapsing-Remitting Multiple Sclerosis (RRMS) from the standpoint of the UK National Health Service (NHS).